bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 24, 2024
Cranial
radiation
therapy
(RT)
for
brain
cancers
is
often
associated
with
the
development
of
radiation-induced
cognitive
dysfunction
(RICD).
RICD
significantly
impacts
quality
life
cancer
survivors,
highlighting
an
unmet
medical
need.
Previous
human
studies
revealed
a
marked
reduction
in
plasma
brain-derived
neurotrophic
factor
(BDNF)
post-chronic
chemotherapy,
linking
this
decline
to
substantial
among
survivors.
Moreover,
riluzole
(RZ)-mediated
increased
BDNF
Ecotoxicology and Environmental Safety,
Journal Year:
2024,
Volume and Issue:
279, P. 116504 - 116504
Published: May 24, 2024
Cranial
radiotherapy
is
a
major
treatment
for
leukemia
and
brain
tumors.
Our
previous
study
found
abscopal
effects
of
cranial
irradiation
could
cause
spermatogenesis
disorder
in
mice.
However,
the
exact
mechanisms
are
not
yet
fully
understood.
In
study,
adult
male
C57BL/6
mice
were
administrated
with
20
Gy
X-ray
(5
per
day
4
days
consecutively)
sacrificed
at
1,
2
weeks.
Tandem
Mass
Tag
(TMT)
quantitative
proteomics
testis
was
combined
bioinformatics
analysis
to
identify
key
molecules
signal
pathways
related
weeks
after
irradiation.
GO
showed
that
closely
oxidative
stress
inflammation.
Severe
occurred
testis,
serum
brain,
while
serious
inflammation
also
serum.
Additionally,
sex
hormones
hypothalamic-pituitary-gonadal
(HPG)
axis
disrupted.
PI3K/Akt
pathway
activated
which
upstream
molecule
SCF/C-Kit
significantly
elevated.
Furthermore,
proliferation
differentiation
ability
spermatogonial
stem
cells
(SSCs)
altered.
These
findings
suggest
can
through
brain-blood-testicular
cascade
stress,
secretory
dysfunction
HPG
axis,
SCF/C-kit
drive
this
process
activating
pathway.
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 24, 2024
Cranial
radiation
therapy
(RT)
for
brain
cancers
is
often
associated
with
the
development
of
radiation-induced
cognitive
dysfunction
(RICD).
RICD
significantly
impacts
quality
life
cancer
survivors,
highlighting
an
unmet
medical
need.
Previous
human
studies
revealed
a
marked
reduction
in
plasma
brain-derived
neurotrophic
factor
(BDNF)
post-chronic
chemotherapy,
linking
this
decline
to
substantial
among
survivors.
Moreover,
riluzole
(RZ)-mediated
increased
BDNF